Issue of Equity

    DERMASALVE SCIENCES PLC                            

                                ISSUE OF EQUITY                                

The Directors of DermaSalve Sciences plc (the "Company") are pleased to
announce that the Company has raised £260,000 through the placing of 6,933,333
new ordinary shares of 1p each (the "Placing Shares") at a price of 3.75p per
share (the "Placing").

Certain of the Directors have subscribed for Placing Shares as detailed below:

Director                Placing Shares  No. of shares held  % of shares held
                      being subscribed         immediately       immediately
                                   for       following the     following the
                                                   Placing           Placing
                                                                            
Dr. Mark Randle              2,000,000          11,365,249            10.33%
                                                                            
Phil Pattison                  400,000             651,980             0.59%
                                                                            
Dr. Clive Morton               133,333             142,423             0.13%
                                                                            
Graham Ashley                  533,333           2,033,333             1.85%
                                                                            
Dr. David Stone                400,000             400,000             0.36%
                                                                            
Dr. Erling Refsum              133,333             133,333             0.12%

The participation of the Directors in the Placing constitutes a related party
transaction under the AIM Rules for Companies. Karl Watkin and Neil Wilson, the
Directors who are not participating in the Placing, consider, having consulted
with Hanson Westhouse Limited, the Company's nominated adviser, that the terms
of the placing of shares with Directors are fair and reasonable insofar as
shareholders are concerned.

Application is being made for the Placing Shares to be admitted to trading on
AIM, which is expected to take place on 27 February 2008. Following the
Placing, the enlarged share capital of the Company will be 110,017,891 ordinary
shares of 1p each. The Placing Shares will represent 6.3 per cent of the issued
share capital of the Company as enlarged by the Placing.

The Placing Shares rank pari passu in all respects with the existing issued
ordinary shares of 1p each, with each share carrying the right to one vote.

Dr. Mark Randle, Chief Executive Officer, said: "The proceeds of the Placing
will be used to fund the initial supply of stock to deliver against firm
contracts which we expect will result in the positive cash flow that we have
all been working towards. I am pleased to see such widespread support for this
share issue from my fellow board members."

Enquiries                                                                    
                                                                             
Dermasalve Sciences plc Dr. Mark       0191 260 5070                         
Randle                                                                       
                                                                             
Hanson Westhouse Limited Tim Feather / 0113 246 2610                         
Matthew Johnson                                                              
                                                                             
St Helens Capital                      020 7628 5582                         
                                                                             
Andy McLintock                                                               
                                                                             
Hansard Group Brendan Adams            020 7245 1100                         



END